Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPIV vaccine safety and immunogenicity in healthy adults
NCT02952833Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZPIV in Zika virus infection, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2016; status: completed.
02
Drugs
ZPIV
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02952833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952833.